Keenova Therapeutics reports positive Phase 3 results
Keenova Therapeutics (NYSE:MNK) reported positive top-line Phase 3 clinical trial results for its injectable enzyme therapy XIAFLEX in adult patients suffering from progressive plantar fibromatosis.











